Pharma Exclusives Pressreleases
Novo Nordisk submits proposal to acquire Metsera, Inc.
Thursday, October 30, 2025Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera Inc MetseraNovo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera Inc Metsera
EMA Grants PRIME Designation to MimeTech S.r.l. for Investigational Drug Udonitrectag Lysine in the Treatment of Diabetic Foot Ulcers (DFU)
Wednesday, October 29, 2025MimeTech Srl today announced that the European Medicines Agency EMA has granted PRIority MEdicines PRIME designation to its investigational drug Udonitrectag lysine for the treatment of diabetic foot ulcers DFU
Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan
Tuesday, October 28, 2025Kyowa Kirin Co Ltd and Orchard Therapeutics announced that Japans Ministry of Health Labor and Welfare MHLW has granted Orphan Regenerative Medicine Product Designation to OTL also known
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
Tuesday, October 28, 2025Roche announced today statistically significant and clinically meaningful results from the phase III INShore study of GazyvaGazyvaro obinutuzumab in children and young adults aged years with idiopathic nephrotic syndrome INS The study met its prima...
Lundbeck and OpenAI join forces to unlock innovation and boost productivity
Monday, October 27, 2025H Lundbeck AS Lundbeck today announced a strategic collaboration with OpenAI to transform how the company innovates and operates across its entire value chain from molecule to patient Through the deployment of ChatGPT Enterprise
Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept
Wednesday, October 15, 2025Quotient Sciences a leading global drug development research and manufacturing accelerator and Biorasi a global clinical research organization CRO today announced a strategic partnership to deliver fully integrated early phase clinical trial solution...
BioMed X Launches Women’s Health R&D Accelerator in Heidelberg
Tuesday, October 14, 2025BioMed X today announced the launch of XFem Labs a new Womens Health RD Accelerator in Heidelberg The purpose of this initiative which is supported by the Gates Foundation is to establish a worldclass womens
Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
Monday, October 13, 2025Lundbeck today announced that its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies DEEs has been granted Breakthrough Therapy Designation BTD by Chinas Center for Drug Evaluat...
WHO Foundation and Lilly Collaborate to Support Global Dementia Action Plan
Monday, October 13, 2025The WHO Foundation and Lilly have announced a collaboration to financially support the aims of the World Health Organizations global action plan on the public health response to dementia
Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel
Monday, October 06, 2025Rochein collaboration with KlinRisk Inc has received the CEmark for the first AIbased risk stratification tool to assess progressive decline in kidney function This milestone allows Roche to introduce the Chronic Kidney Disease CKD
